Communiqués Phio Pharmaceuticals Corp.

Actions

PHIO

US71880W5013

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 20/07/2026 Varia. 5j. Varia. 1 janv.
1,080 USD +4,85% Graphique intraday de Phio Pharmaceuticals Corp. +5,88% +2,86%

Communiqués

15/07 Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision NE
26/06 Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series NE
25/06 Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026 NE
24/06 Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 NE
18/06 Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 NE
26/05 Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series NE
12/05 Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026 NE
08/05 Phio Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) PU
07/05 Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update NE
23/04 Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series NE
13/04 Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 NE
09/04 Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 NE
30/03 Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 NE
23/03 Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement NE
16/03 Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office NE
10/03 Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT AQ
10/03 Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT NE
05/03 Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update NE
05/03 Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series NE
23/02 Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company EQ
19/02 Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 NE
10/02 Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial NE
26/01 Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference NE
20/01 Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial NE
15/01 Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026 NE
Aucun résultat pour cette recherche